Literature DB >> 30980126

Prognostic value of ADC quantification for clinical outcome in uterine cervical cancer treated with concurrent chemoradiotherapy.

Kyo-Won Gu1, Chan Kyo Kim2,3,4, Chel Hun Choi5, Young Cheol Yoon1, Won Park6.   

Abstract

OBJECTIVES: To investigate the prognostic value of diffusion-weighted imaging (DWI) in predicting clinical outcome in patients with cervical cancer after concurrent chemoradiotherapy (CCRT).
METHODS: We enrolled 124 cervical cancer patients who received definitive CCRT and underwent 3 T-MRI before and 1 month after initiating treatment. The mean apparent diffusion coefficient (ADC) value was measured on the tumor and the changes in ADC percentage (ΔADCmean) between the two time points were calculated. The Cox proportion hazard model was used to evaluate the associations between imaging or clinical variables and progression-free survival (PFS), cancer-specific survival (CSS), and overall survival (OS).
RESULTS: In multivariate analysis, ΔADCmean was the only independent predictor of PFS (hazard ratio [HR] = 0.2379, p = 0.005), CSS (HR = 0.310, p = 0.024), and OS (HR = 0.217, p = 0.002). Squamous cell carcinoma antigen, histology, and pretreatment tumor size were significantly independent predictors of PFS. Tumor size response was significantly independent predictor of CSS and OS. Using the cutoff values of ΔADCmean, the PFS was significantly lower for ΔADCmean < 27.8% (p = 0.001). The CSS and OS were significantly lower for ΔADCmean < 16.1% (p = 0.002 and p < 0.001, respectively).
CONCLUSION: The percentage change in tumor ADC may be a useful predictor of disease progression and survival in patients with cervical cancer treated with CCRT. KEY POINTS: • DWI is widely used as a potential marker of tumor viability. • Percentage change in tumor ADC (ΔADC mean ) was an independent marker of PFS, CSS, and OS. • Survival was better in patients with ≥ ΔADC mean cutoff value than with < the cutoff value.

Entities:  

Keywords:  Cervical cancer; Concurrent chemoradiotherapy; Diffusion-weighted imaging; Magnetic resonance imaging; Treatment outcome

Mesh:

Year:  2019        PMID: 30980126     DOI: 10.1007/s00330-019-06204-w

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  7 in total

1.  Imaging Biomarkers and Liquid Biopsy in Assessment of Cervical Cancer.

Authors:  Mansur A Ghani; Joy Liau; Ramez Eskander; Loren Mell; Tahir Yusufaly; Sebastian Obrzut
Journal:  J Comput Assist Tomogr       Date:  2022-08-16       Impact factor: 2.081

2.  MRI outcome evaluation in patients with IB2 and IIA2 squamous cervical cancer stages: preliminary results.

Authors:  Qingling Song; Huiting Pang; Rui Tong; Yanmei Zhu; Yahong Luo; Tao Yu; Fan Liu; Yue Dong
Journal:  Insights Imaging       Date:  2022-09-16

3.  Combination of Radiomics and Machine Learning with Diffusion-Weighted MR Imaging for Clinical Outcome Prognostication in Cervical Cancer.

Authors:  Ankush Jajodia; Ayushi Gupta; Helmut Prosch; Marius Mayerhoefer; Swarupa Mitra; Sunil Pasricha; Anurag Mehta; Sunil Puri; Arvind Chaturvedi
Journal:  Tomography       Date:  2021-08-05

4.  Intravoxel Incoherent Motion (IVIM) MR Quantification in Locally Advanced Cervical Cancer (LACC): Preliminary Study on Assessment of Tumor Aggressiveness and Response to Neoadjuvant Chemotherapy.

Authors:  Miriam Dolciami; Silvia Capuani; Veronica Celli; Alessandra Maiuro; Angelina Pernazza; Innocenza Palaia; Violante Di Donato; Giusi Santangelo; Stefania Maria Rita Rizzo; Paolo Ricci; Carlo Della Rocca; Carlo Catalano; Lucia Manganaro
Journal:  J Pers Med       Date:  2022-04-15

5.  Diagnosis Value of Colposcope Combined with Serum Squamous Cell Carcinoma Antigen, Carbohydrate Antigen 125, and Carcinoembryonic Antigen for Moderate to Advanced Cervical Cancer Patients Treated with Modified Fuzheng Peiyuan Decoction.

Authors:  Huijuan Meng; Yulan Zhang; Youguo Chen
Journal:  Evid Based Complement Alternat Med       Date:  2021-12-31       Impact factor: 2.629

6.  Predicting factors for primary cervical cancer recurrence after definitive radiation therapy.

Authors:  Mitsuru Okubo; Tomohiro Itonaga; Tatsuhiko Saito; Sachika Shiraishi; Daisuke Yunaiyama; Ryuji Mikami; Akira Sakurada; Shinji Sugahara; Koichi Tokuuye; Kazuhiro Saito
Journal:  BJR Open       Date:  2021-11-24

7.  Role of ADC values in assessing clinical response and identifying residual disease post-chemo radiation in uterine cervix cancer.

Authors:  Ankush Jajodia; Vivek Mahawar; Arvind K Chaturvedi; Avinash Rao; Rishu Singla; Swarupa Mitra; Sumit Goyal; Sikha Kesan; Sunil Pasricha; Udip Maheshwari; Rupal Tripathi; Venkata Pradeep Babu Koyyala
Journal:  Indian J Radiol Imaging       Date:  2019-12-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.